Recombinant Human CBG protein

中文名： 皮质醇结合球蛋白(CBG)重组蛋白
别名： CBG；CBG；Corticosteroid-binding globulin

货号: PA1000-6339

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>95%SDS-PAGE.
种属	Human
靶点	CBG
Uniprot No	P08185
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	23-405aa
氨基酸序列	MDPNAAYVNMSNHHRGLASANVDFAFSLYKHLVALSPKKNIFISPVSISM ALAMLSLGTCGHTRAQLLQGLGFNLTERSETEIHQGFQHLHQLFAKSDTS LEMTMGNALFLDGSLELLESFSADIKHYYESEVLAMNFQDWATASRQINS YVKNKTQGKIVDLFSGLDSPAILVLVNYIFFKGTWTQPFDLASTREENFY VDETTVVKVPMMLQSSTISYLHDAELPCQLVQMNYVGNGTVFFILPDKGK MNTVIAALSRDTINRWSAGLTSSQVDLYIPKVTISGVYDLGDVLEEMGIA DLFTNQANFSRITQDAQLKSSKVVHKAVLQLNEEGVDTAGSTGVTLNLTS KPIILRFNQPFIIMIFDHFTWSSLFLARVMNPVLDHHHHHH
预测分子量	44 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是3篇关于CBG(大麻萜酚)重组蛋白研究的模拟参考文献示例(注：文献为虚构示例，实际文献请通过学术数据库检索)：

---

1. **文献名称**：*Heterologous Production of Cannabigerol in Engineered Saccharomyces cerevisiae via Metabolic Engineering*

**作者**：Zhang, L. et al.

**摘要**：研究利用酿酒酵母异源表达大麻萜酚(CBG)合成关键酶(如CBGA合酶)，通过代谢工程优化萜类前体供应，实现CBG的高效生物合成，产量达到120 mg/L。

---

2. **文献名称**：*Optimization of CBG Biosynthesis in E. coli through Promoter and Codon Usage Engineering*

**作者**：Smith, J.R. & Patel, K.

**摘要**：通过优化大肠杆菌中CBG合成相关基因的启动子及密码子使用偏好，结合发酵条件调控，显著提高CBG前体橄榄酸(olivetolic acid)的产量，为规模化生产提供策略。

---

3. **文献名称**：*Structural and Functional Characterization of Recombinant CBG Synthase from Cannabis sativa*

**作者**：Lee, H. et al.

**摘要**：首次解析大麻来源CBG合酶的重组蛋白晶体结构，阐明其催化机制，并通过体外酶反应验证其对大麻萜酚酸(CBGA)合成的特异性，为酶工程改造奠定基础。

---

**建议**：实际研究中，可检索PubMed、Web of Science等平台，关键词包括“recombinant CBG synthase”、“heterologous production of cannabigerol”或结合具体研究方向(如代谢工程、蛋白纯化)。

背景信息

Cannabigerol (CBG) recombinant protein is a biotechnologically engineered molecule derived from the cannabinoid biosynthetic pathway. CBG, a non-psychoactive phytocannabinoid found in *Cannabis sativa*, serves as a precursor to major cannabinoids like THC and CBD. Its growing therapeutic potential—including anti-inflammatory, neuroprotective, and antimicrobial properties—has driven interest in scalable production methods. Traditional plant extraction is inefficient due to low CBG content (<1% in most strains) and legal complexities. Recombinant protein technology offers a sustainable alternative by expressing key enzymes (e.g., CBG synthase) in heterologous systems like *E. coli*, yeast, or plant cell cultures.

The process involves cloning genes encoding CBG-biosynthetic enzymes into microbial hosts, optimizing fermentation conditions to maximize yield. Recombinant CBG synthase catalyzes the conversion of olivetolic acid and geranyl pyrophosphate into CBGA, which is then decarboxylated to CBG. This approach enhances purity, reduces contamination risks, and bypasses agricultural challenges. Recent advances in synthetic biology and CRISPR editing have further improved enzyme stability and production rates.

CBG recombinant proteins are pivotal for pharmaceutical R&D, enabling standardized studies on cannabinoid receptors (CB1/CB2) and their signaling pathways. They also support industrial-scale manufacturing of CBG-based therapeutics, cosmetics, and nutraceuticals. However, challenges persist, including high fermentation costs, regulatory hurdles, and the need for enzyme engineering to boost catalytic efficiency. Ongoing research focuses on metabolic pathway optimization and novel host systems to meet rising global demand while adhering to sustainability goals.